Every 42 seconds, someone in the United States will suffer a heart attack. For many, the amount of heart damage will be large. Others will experience recurrent heart attacks. Unfortunately, the human heart cannot self-heal and cumulative heart damage leads to heart enlargement, decreased contraction force, congestive heart failure, and eventually death.
CFX™ Solus, which is an application-specific formulation of CFX™, can halt the inflammatory processes that lead to chronic scarring and heart failure following myocardial infarction. CFX™ Solus modifies inflammation-directed cells called macrophages into a tissue repair state. We envision percutaneously injecting CFX™ Solus into recently infarcted heart tissue, to reduce inflammation, induce natural tissue repair responses and prevent future heart failure progression.